NCT07532226 A Study of Guselkumab Treatment Persistence in Psoriatic Arthritis Participants
| NCT ID | NCT07532226 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Janssen-Cilag Ltd. |
| Condition | Arthritis, Psoriatic |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2026-04-17 |
| Primary Completion | 2029-12-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2026-04-17 with a primary completion date of 2029-12-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This observational study aims to assess the 1-year persistence of guselkumab in adult patients with psoriatic arthritis (an inflammatory disease that affects the joints in participants with psoriasis, a skin condition that causes red, scaly patches).
Eligibility Criteria
Inclusion criteria: * Have a confirmed diagnosis of psoriatic arthritis (PsA) as determined by a rheumatologist with reference to ClASsification criteria for Psoriatic ARthritis (CASPAR) * Start guselkumab as a first, second, third, or fourth line of disease-modifying antirheumatic drug (bDMARD) therapy for the indication of PsA as part of standard clinical practice at the time of enrollment into the observational study * Initiating guselkumab treatment according to Summary of Product Characteristics (SmPC) indication * The treatment decision must be taken by the participating rheumatologist prior to, and independently of the patient's inclusion into the study, following clinical practice in accordance with local and overarching guidelines and local regulations * Must have received the information note, given his/her oral agreement and has not objected to the collection of his/her data in accordance with French requirements Exclusion Criteria: * Have already taken a specific interleukin-23 inhibitor (IL-23i) treatment. * Are receiving combination therapy: 2 or more targeted therapies (biotherapy, Janus kinase \[JAK\] inhibitor, phosphodiesterase 4 (PDE4) inhibitor) indicated for PsA/PsO at the same time * Has a contra-indication to guselkumab according to the SmPC (for hypersensitivity or due to active clinically important infection, example active tuberculosis) * Unwilling or unable to participate in long-term data collection * Received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 30 days before the start of the study ( that is, signing of informed consent) * Currently enrolled in any interventional study or any Janssen-Cilag France-sponsored observational clinical study * Is under guardianship or curatorship, judicial protection, future protection mandate or under family authorization
Contact & Investigator
Janssen-Cilag France Clinical Trial
STUDY DIRECTOR
Janssen-Cilag France
Frequently Asked Questions
Who can join the NCT07532226 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Arthritis, Psoriatic. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07532226 currently recruiting?
Yes, NCT07532226 is actively recruiting participants. Contact the research team at Participate-In-This-Study1@its.jnj.com for enrollment information.
Where is the NCT07532226 trial being conducted?
This trial is being conducted at Lille, France.
Who is sponsoring the NCT07532226 clinical trial?
NCT07532226 is sponsored by Janssen-Cilag Ltd.. The principal investigator is Janssen-Cilag France Clinical Trial at Janssen-Cilag France. The trial plans to enroll 200 participants.